Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Olivia Pagani, Meredith M Regan, Barbara A Walley, Gini F Fleming, Marco Colleoni, Istvan Lang, Henry L Gomez, Carlo Tondini, Harold J Burstein, Edith A Perez, Eva Ciruelos, Vered Stearns, Herve R Bonnefoi, Silvana Martino, Charles E Geyer, Graziella Pinotti, Fabio Puglisi, Diana Crivellari, Thomas Ruhstaller, Eric P Winer Show all
NEW ENGLAND JOURNAL OF MEDICINE | MASSACHUSETTS MEDICAL SOC | Published : 2014
BACKGROUND: Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor-positive breast cancer. METHODS: In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor-positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation. The primary analysis combined data from 4690 patients in the two trials. RESULTS: After a median follow-up of ..View full abstract
Awarded by NATIONAL CANCER INSTITUTE
Awarded by NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Supported by Pfizer, Ipsen, the International Breast Cancer Study Group, and the National Cancer Institute.Dr. Fleming reports receiving a study drug for investigation in a clinical trial from Corcept Therapeutics; Dr. Colleoni, receiving fees for serving on advisory boards from Boehringer Ingelheim, Taiho Pharmaceutical, AbbVie, and AstraZeneca and consulting and lecture fees from Novartis; Dr. Stearns, receiving grant support from Pfizer and Novartis; Dr. Ruhstaller, receiving travel support and fees for serving on an advisory board from Novartis; and Dr. Viale, receiving fees for serving on advisory boards from Novartis, Roche, and Eli Lilly. No other potential conflict of interest relevant to this article was reported.